SALT LAKE CITY, UT--(MARKET WIRE)--Aug 16, 2007 -- Myriad Genetics, Inc. (NasdaqGS:MYGN - News) (www.myriad.com) announced today that it has initiated a third Phase 2 human clinical trial of its therapeutic candidate, Azixa(TM) (MPC-6827), in patients with non-small-cell lung cancer that has spread to the brain. The two previously announced Phase 2 trials are studying primary brain cancer and melanoma that has spread to the brain.
